WS
KIN

Wedbush Securities’s Kindred Biosciences, Inc. KIN Stock Holding History

Wedbush Securities’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,000
Closed -$87K – 919
2018
Q1 		$87K Hold
10,000
– – 0.01% 765
2017
Q4 		$95K Buy
+10,000
New +$78.1K 0.01% 789

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
PVAM
Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

Wedbush Securities's KIN Position: Q2 2018 in Review

Wedbush Securities sold out of Kindred Biosciences, Inc. (KIN) in Q2 2018, closing a stake of 10,000 shares — an estimated $87K sold.

Wedbush Securities first reported a position in KIN in Q4 2017 and held it in 2 quarters. The position peaked at $95K in Q4 2017. 73 funds tracked by Wall St. Rank hold KIN as of Q2 2018.

  • Wedbush Securities reported no remaining Kindred Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • Wedbush Securities sold 10,000 Kindred Biosciences, Inc. shares in Q2 2018, an estimated $87K.
  • Wedbush Securities first reported a position in Kindred Biosciences, Inc. in Q4 2017 and held it in 2 quarters.
  • Wedbush Securities's Kindred Biosciences, Inc. position peaked at $95K in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2018.

Based on Wedbush Securities's 13F filing for Q2 2018, filed 3 Aug 2018.